N- ACETYL - L - CYSTEINE FOR TREATMENT OF POLYCYSTIC OVARY SYNDROME

The invention relates to a new prescription of NAC in the treatment of polycystic ovary syndrome (PCOS) and of symptoms associated with PCOS, in a human or mammalian animal patient. In addition an effective dose range of NAC in the treatment of PCOS is proposed, wherein the patient is treated for at least two months in a pulsed or intermittent fashion. The prescribed treatment regimen may be used e.g. in order to reduce ovary volume and number of follicles, achieve regular menstrual cycle, promote a desired pregnancy, ameliorate acne and/or hirsutism and reduce body mass index (BMI) in a subject with PCOS. Side effects of this treatment are virtually absent and, in particular, this treatment does not hinder pregnancy.